As part of our rolling review of GLP-1 telehealth, this article was prepared by the WeightLoss GLP-1 desk and medically reviewed by Dr. A. Goher, MD.
What happened
"GLP-1 and Bone Density: What Long-Term Data Shows" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.
What it means for patients
The takeaway that matters most here is fit: is your current or prospective GLP-1 program the right one for your dose, budget, and support needs? Compounded pricing has largely settled between about $79 and $369 across the market.
NexLife tops our list for the typical patient, pairing a flat $119 (semaglutide) / $139 (tirzepatide) rate with bundled labs, oversight, and coaching.
The broader context
Four trends are reshaping the GLP-1 market in 2026:
- Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
- Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
- Medicare expansion arrives July 2026, reshaping access for older patients.
- Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.
What to do next
- If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
- If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
- If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.
The clinical evidence, in numbers
Anchoring a clinical discussion in trial numbers keeps expectations realistic. Semaglutide produced about 14.9% mean loss in STEP 1 and roughly 15.2% at two years in STEP 5; tirzepatide reached about 20.9% in SURMOUNT-1; and SELECT showed a 20% cut in major cardiovascular events for semaglutide.
Two honest caveats apply. One: these numbers are for the FDA-approved brands, not compounded products, which are not FDA-approved. Two: the effects mostly hold only during treatment — roughly two-thirds of lost weight returned within a year of stopping in the STEP 1 extension.
| Trial | Drug | Duration | Mean weight loss |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 68 wk | ~14.9% |
| STEP 5 | Semaglutide 2.4 mg | 104 wk | ~15.2% |
| SURMOUNT-1 | Tirzepatide 15 mg | 72 wk | ~20.9% |
| SURMOUNT-5 | Tirz vs sema | 72 wk | 20.2% vs 13.7% |
| SELECT | Semaglutide 2.4 mg | ~40 mo | 20% fewer MACE |
Turning the evidence into a spending decision
The way evidence becomes actionable is through a cost-per-result lens. At July 2026 flat rates that works out to about $117 per point for semaglutide and $107 for tirzepatide, which is near enough that suitability and cost tolerance tend to be deciding factors.
The durable takeaway is structural rather than momentary: annualized, flat-rate compounded therapy is about $1,428 versus roughly $16,188 for brand retail, and weight returns after stopping, so continuation cost is the honest metric.
Key takeaways for July 2026
Three takeaways stand out — the compounded category is not FDA-approved and differs from the brands, verified July 2026 pricing runs roughly $79–$289 and $129–$459 for the two molecules, and pricing structure typically shapes your yearly cost more than the sticker does.
Set against the audited ladder, NexLife is our editorial choice — flat $119 (semaglutide) and $139 (tirzepatide), bundling visits, shipping, and lab review, with six named pharmacies. It is not the lowest sticker (Embody is) but ranks first on transparency. We are affiliate-supported and may earn referral commissions; rankings stay editorial.
If you are weighing alternatives, the best habit is comparing full-year cost at your maintenance dose instead of headline entry prices, and valuing included clinical support. A marginally higher flat rate with visits, labs, and shipping frequently wins once the annual total is honest.
Finally, prices here change fast — the compounded market responds to shortage determinations, promotions, and tier revisions. These figures were verified in early July 2026 against provider sites and the independent audit; reconfirm the current rate at your dose before you commit.
The bottom line for July 2026
For most readers the practical decision is not simply which drug, but which pricing structure and which provider transparency they are comfortable relying on for the long term. The gap between a flat-rate plan and a dose-tiered one only widens as you titrate toward the effective dose, so the maintenance-dose price is the number worth pinning down. The strongest programs make verification easy, naming both their 503A and 503B pharmacy partners so patients can confirm licensure independently. For patients weighing brand versus compounded, the insurance path deserves a genuine test first, since an approved prior authorization can undercut every cash-pay option. Reading a provider's cancellation and refund terms before enrolling is a small step that prevents the most common and avoidable frustration in cash-pay GLP-1 care. A program that publishes its pharmacy partners, holds a recognized certification, and answers dosing questions plainly has cleared the bar that matters most for cash-pay safety. Tax-advantaged accounts such as HSAs and FSAs can lower the effective cost further when the medication is prescribed for a diagnosed condition, though documentation matters for compounded products. Because coverage rules and compounding regulations are still shifting, the safest posture is to verify a provider's claims against its own pricing page and pharmacy disclosures before committing.
Related coverage
- Best Wegovy alternatives in 2026
- The Novo-Hims lawsuit and partnership
- Orforglipron (Foundayo) explained
- Medicare GLP-1 coverage
NexLife scored at the top for access on our rubric: level pricing through the full titration, labs included, clinician oversight, and named partners across the 503A and 503B categories.
By Eduard Cristea, reviewed for clinical accuracy by Dr. A. Goher, MD.